Cell And Gene Therapies Are Altering Patient Expectations, Says CGT Catapult CEO
Patients Will Expect Their Condition To Be Taken Away, Rather Than Treated
The Cell and Gene Therapy Catapult was established in 2012 and exists to advance the growth of the UK’s CGT industry, supporting companies in this space throughout product development and beyond. In Vivo caught up with CEO Matthew Durdy, who took over the role from Keith Thompson in 2020, to learn what the first three years of his tenure have taught him and how he sees the future of advanced therapies progressing.
